Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder | Zendy

Michelle R. Lofwall | Zendy; Sharon Walsh | Zendy; Edward V. Nunes | Zendy; Genie L.﻿ Bailey | Zendy; Stacey C. Sigmon | Zendy; Kyle M. Kampman | Zendy; Michael Frost | Zendy; Fredrik Tiberg | Zendy; Margareta Linden | Zendy; Behshad Sheldon | Zendy; Sonia Oosman | Zendy; Stefan Peterson | Zendy; Michael Chen | Zendy; Sonnie Kim | Zendy

Open Access

Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder

Author(s) -

Michelle R. Lofwall,

Sharon Walsh,

Edward V. Nunes,

Genie L. Bailey,

Stacey C. Sigmon,

Kyle M. Kampman,

Michael Frost,

Fredrik Tiberg,

Margareta Linden,

Behshad Sheldon,

Sonia Oosman,

Stefan Peterson,

Michael Chen,

Sonnie Kim

Publication year - 2018

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2018.1052

Subject(s) - buprenorphine , medicine , opioid use disorder , placebo , opioid , anesthesia , randomization , randomized controlled trial , (+) naloxone , alternative medicine , receptor , pathology

Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore